Since its founding in 2012, SDS Life Science has grown into a multi-disciplinary team of handpicked specialists with regulatory and scientific knowledge in medicinal product development and statistics. Our ambition is to guide our clients in transforming their research hypotheses into full clinical studies. We adopt a holistic approach in collaboration with our clients to provide the best solutions for each unique project. Our passion is to solve those tricky questions which have no obvious answers.
We combine excellence and experience
Jens Hansson is the CEO and chairman of the board and a highly experienced company builder making use of a multitude of competences achieved from almost 30 years of mid- and top management positions within the financial and manufacturing industries. He is a strong leader with high team-working ethics, bringing together talent and empowering team members to reach established goals effectively. Jens leadership is built on inspiration, responsiveness and stability, all of which will be of much importance in SDS growth journey.
Gösta Hiller joined SDS in early 2017 and holds a PhD in Cell and Molecular Biology from Lund University, Sweden. Prior to joining SDS, Gösta worked as a preclinical researcher, screening and characterizing new chemical series and as a clinical and global project manager for several years and he brings more than 15 years´ drug development experience to SDS. His role is to assist clients at both strategic and operational levels, particularly in the delivery of early and late stage clinical development programs involving both small molecules and biologics. Gösta is also SDS’s Chief Operating Officer.
Anna is a founder of Scandinavian Development Services (SDS) Group and holds a PhD in Biostatistics from Karolinska Institutet, Stockholm. Her varied experience comes from work within regulatory authorities, the pharmaceutical industry and academic research. She has long-standing industry experience as a consultant within regulatory affairs and drug clinical trials at Pfizer Pharmaceuticals, Pharmacia & Upjohn and Zeneca Pharmaceuticals, to name a few. Anna's expertise lies within clinical development and she is particularly interested in merging statistical and regulatory knowledge to create studies better suited for regulatory needs.
Anna Torrång has a BSc in Statistics from the University of Linköping, Sweden, and a long and broad experience (>25 years) from the pharmaceutical industry and epidemiological research at the Karolinska Institute in Stockholm. Within AstraZeneca she worked as a Global Product Statistician in projects within neuroscience and as a Group Manager for Biostatisticians. Her main expertise lies within clinical development, and the design and statistical analysis of clinical trials. Anna has worked at SDS since 2013, primarily as a senior biostatistical consultant in drug development and as the Director for SDS Biostatistics.
Anna Sandholm holds a PhD in Environmental Chemistry from Stockholm University, in the scientific area of Drug Metabolism and Pharmacokinetics. Anna has extensive experience from the pharmaceutical industry and from academic research.
Anna has worked extensively with candidate drug selection and early-to-late drug development across a broad range of indications. She has significant knowledge of regulatory guidelines and recommendations, and a solid understanding of how to best apply them while maintaining focus on the overall scientific rationale.
Her core competence is nonclinical and early clinical projects from a scientific, strategic and regulatory perspective. She has worked at SDS since 2012, primarily as a senior consultant in drug development and as Director for SDS Nonclinical and DMPK.
Maria Wanderoy holds a PhD in Neurochemistry and Neurotoxicology from Stockholm University, Sweden. Maria brings more than 20 years’ experience from the Pharmaceutical Industry in roles ranging from Global-, Clinical- and Preclinical Project Manager to Senior Research Scientist which gives her a broad understanding of the Drug Development process all the way from early Discovery to clinical trial planning and execution in Clinical Development. Maria is responsible for Clinical Project Management at SDS including the effort providing a high-quality integrated Phase I solution to our customers. Furthermore, she is advising clients on both strategic and operational levels, particularly in the field of design and delivery of early Clinical Development programs. Maria joined SDS in 2018 as a Senior Advisor Clinical Project Management.
Lars Lund-Roland has a marketing and business background and works as a management and business consultant. Lars has recently been CEO of Bringwell AB(pub), a Nordic health and welfare company listed in Stockholm, that commercializes OTC pharmaceuticals, nutrition and food supplements. He has also been Managing Director of MSD Norway (Merck & Co Inc. subsidiary) for 10 years and has more than twenty-five years’ experience from various executive positions within marketing and sales at Merck. He also serves as board member of Vaccibody AS and has served as member of the board of Targovax ASA, another immunotherapy company in the oncology field; as well as the board of Infodoc AS and Health Tech AS, two Norwegian health technology companies and the Norwegian Association of Pharmaceutical Manufacturers.
Anna Holmberg joined SDS in early 2021 and holds a PhD in Physical Chemistry from Lund University, Sweden. Anna brings more than 20 years’ experience from managing research and development projects in the life science sector. Prior to joining SDS Anna was CEO of Pharmiva AB, a Swedish medical device company within FemTech. She has also been CEO of Zelmic AB a CRO focused on the development of topical and transdermal pharmaceutical formulations. Annas is responsible for SDS business in the south of Sweden.
Erika Spens started working at SDS Life Science in 2021 as director for regulatory affairs. Erika has 15+ years of experience from the pharmaceutical industry, both within small and largerenterprises. Before she started working at SDS, she held a position as director for global regulatory affairs at a parent company, working with early development, market registrations, and post approval activities in Europe, US, and rest of the world. Furthermore, she has experience from project management of development programs and large business collaborations. Erika holds a Master of Science from Uppsala University and a PhD in bioprocess technology from The Royal Institute of Technology (KTH) in Sweden. Erika's passion is to develop regulatory strategies with the best chance of success for a given product in development.